#POLB Poolbeg Pharma PLC – Appointment of Dr Adrian Kilcoyne to SAB March 12, 2026 – Posted in: Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board. Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome…

#POLB Poolbeg Pharma PLC – SAB Endorses Influenza Drug Targets October 26, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

26 October 2023 – (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that its Scientific Advisory Board (‘SAB’) has endorsed the influenza drug targets identified in its AI-led drug discovery programme. Key highlights · Prioritisation of influenza drug targets which have the highest likelihood of success · New potential collaborative routes to maximise the impact of the outputs identified · Ongoing discussions with…

#POLB Poolbeg Pharma PLC – Appointment of Dr Adrian Kilcoyne to SAB March 12, 2026 – Posted in: Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – SAB Endorses Influenza Drug Targets October 26, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL